



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Otenzepad

Cat. No.:	HY-101381		
CAS No.:	102394-31-0		
Molecular Formula:	C ₂₄ H ₃₁ N ₅ O ₂		
Molecular Weight:	421.54		
Target:	mAChR		
Pathway:	GPCR/G Protein; Neuronal Signaling		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 25 mg/mL (59.31 mM; ultrasonic and warming and heat to 60°C)

	Solvent Concentration	Mass	1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM		2.3723 mL	11.8613 mL	23.7225 mL
	5 mM		0.4745 mL	2.3723 mL	4.7445 mL
	10 mM		0.2372 mL	1.1861 mL	2.3723 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

Otenzepad (AF-DX 116) is a selective and competitive M2 muscarinic acetylcholine receptor antagonist, with IC₅₀ values of 640 nM and 386 nM for rabbit peripheral lung and rat heart, respectively^[1].

IC₅₀ & Target

640 nM (M2 muscarinic acetylcholine receptor in rabbit peripheral lung), 386 nM (M2 muscarinic acetylcholine receptor in rat heart)^[1].

In Vivo

Otenzepad (0.5, 1 mg/kg, s.c., in rats) significantly improved win-stay acquisition relative to vehicle-injected controls^[2].
 Otenzepad (2 mg/kg, s.c., in rats) significantly improved retention relative to vehicle controls^[2].
 Otenzepad (0.3, 1.0, or 3.0 mg/kg, ip, in mice) potentiates the effects of glucose and reverses the effects of insulin on memory^[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Forty-eight male Long-Evans rats (325-350 g)^[2].

Dosage:	0.25, 0.5, 1.0 and 2.0 mg/kg.
Administration:	S.C. on the dorsum of the neck once.
Result:	Doses of 0.5 and 1.0 mg/kg significantly improved acquisition relative to vehicle controls, while doses of 0.25 and 2.0 mg/kg had no effect.
Animal Model:	Adult male Swiss mice (age 60–70 days; weight 25–30 g) ^[3] .
Dosage:	0.3, 1.0, or 3.0 mg/kg.
Administration:	IP once.
Result:	Enhanced retention in an inverted-U dose–response manner, with significant enhancement seen at 1.0 mg/kg ($U_{15,15} = 49$, $p < 0.02$, compared with saline-saline-injected control group).

REFERENCES

- [1]. Bloom JW, et al. Heterogeneity of the M1 muscarinic receptor subtype between peripheral lung and cerebral cortex demonstrated by the selective antagonist AF-DX 116. *Life Sci.* 1987 Jul 27;41(4):491-6.
- [2]. Packard MG, et al. Post-training injection of the acetylcholine M2 receptor antagonist AF-DX 116 improves memory. *Brain Res.* 1990 Jul 30;524(1):72-6.
- [3]. Kopf SR, et al. AF-DX 116, a presynaptic muscarinic receptor antagonist, potentiates the effects of glucose and reverses the effects of insulin on memory. *Neurobiol Learn Mem.* 1998 Nov;70(3):305-13.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA